Literature DB >> 32142394

Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.

Patricia A Ganz1,2, Kathleen Van Dyk1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32142394      PMCID： PMC7280046          DOI： 10.1200/JCO.20.00336

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  27 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy.

Authors:  Haryana M Dhillon; Ian F Tannock; Gregory R Pond; Corrinne Renton; Sean B Rourke; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2017-10-27       Impact factor: 4.442

3.  Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study.

Authors:  Patricia A Ganz; Laura Petersen; Steven A Castellon; Julienne E Bower; Daniel H S Silverman; Steven W Cole; Michael R Irwin; Thomas R Belin
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

4.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

Review 5.  Understanding the broad influence of sex hormones and sex differences in the brain.

Authors:  Bruce S McEwen; Teresa A Milner
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

6.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

Authors:  S B Schagen; F S van Dam; M J Muller; W Boogerd; J Lindeboom; P F Bruning
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

Review 7.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

Review 8.  Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?

Authors:  Bauke Buwalda; Sanne B Schagen
Journal:  Life Sci       Date:  2013-01-23       Impact factor: 5.037

9.  Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study.

Authors:  Janette L Vardy; Haryana M Dhillon; Gregory R Pond; Sean B Rourke; Tsegaye Bekele; Corrinne Renton; Anna Dodd; Haibo Zhang; Philip Beale; Stephen Clarke; Ian F Tannock
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.

Authors:  Florien W Boele; Christina M T Schilder; Mari-Lou de Roode; Jan Berend Deijen; Sanne B Schagen
Journal:  Menopause       Date:  2015-01       Impact factor: 2.953
View more
  5 in total

Review 1.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

2.  A randomised wait-list controlled trial to evaluate Emotional Freedom Techniques for self-reported cancer-related cognitive impairment in cancer survivors (EMOTICON).

Authors:  Laura Tack; Tessa Lefebvre; Michelle Lycke; Chistine Langenaeken; Christel Fontaine; Marleen Borms; Marianne Hanssens; Christel Knops; Kathleen Meryck; Tom Boterberg; Hans Pottel; Patricia Schofield; Philip R Debruyne
Journal:  EClinicalMedicine       Date:  2021-08-19

3.  COMT rs737865 mediates chemobrain in breast cancer patients with various levels of Ki-67.

Authors:  Wen Li; Sheng Yu; Xu Duan; Senbang Yao; Lingxue Tang; Huaidong Cheng
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 4.  Animal models of chemotherapy-induced cognitive decline in preclinical drug development.

Authors:  Jeena John; Manas Kinra; Jayesh Mudgal; G L Viswanatha; K Nandakumar
Journal:  Psychopharmacology (Berl)       Date:  2021-10-13       Impact factor: 4.415

5.  Association of APOE4 genotype and treatment with cognitive outcomes in breast cancer survivors over time.

Authors:  Kathleen Van Dyk; Catherine M Crespi; Julienne E Bower; Judith E Carroll; Laura Petersen; Patricia A Ganz
Journal:  NPJ Breast Cancer       Date:  2021-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.